2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Titel:
2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
Auteur:
Kellokumpu-Lehtinen, Pirkko-Liisa Harmenberg, Ulrika Joensuu, Timo McDermott, Ray Hervonen, Petteri Ginman, Claes Luukkaa, Marjaana Nyandoto, Paul Hemminki, Akseli Nilsson, Sten McCaffrey, John Asola, Raija Turpeenniemi-Hujanen, Taina Laestadius, Fredrik Tasmuth, Tiina Sandberg, Katinka Keane, Maccon Lehtinen, Ilari Luukkaala, Tiina Joensuu, Heikki